| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.16.4 |
| P8608 | Fatcat ID | release_fyjgk466tbblxdwhobdveohd2e |
| P698 | PubMed publication ID | 26901457 |
| P50 | author | Nicholas J. Vogelzang | Q7025647 |
| P2093 | author name string | Arun Kannan | |
| Srinath Sundararajan | |||
| Abhijeet Kumar | |||
| Mugilan Poongkunran | |||
| P2860 | cites work | Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis | Q27026453 |
| Ponatinib in refractory Philadelphia chromosome-positive leukemias | Q27851967 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis | Q28480930 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. | Q33404714 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis | Q33558693 | ||
| Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors | Q33698419 | ||
| Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials | Q33795896 | ||
| Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors | Q33828690 | ||
| Vascular endothelial growth factors and vascular permeability | Q33954958 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| The role of nitric oxide in hypertension and renal disease progression | Q34259028 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Management of bleeding in patients with advanced cancer | Q34551788 | ||
| Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 | ||
| Nitric oxide in hypertension | Q34591297 | ||
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 | ||
| Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis | Q34652270 | ||
| Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials | Q34654605 | ||
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 | ||
| Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials | Q34900938 | ||
| Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib | Q34916352 | ||
| Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts | Q35909225 | ||
| Vascular endothelial growth factor and angiogenesis | Q35985850 | ||
| Management of antiangiogenic therapy-induced hypertension | Q36170252 | ||
| Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia | Q36316309 | ||
| Mechanisms of adverse effects of anti-VEGF therapy for cancer | Q36609627 | ||
| Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1 | Q36627125 | ||
| Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies | Q36714379 | ||
| Molecularly targeted oncology therapeutics and prolongation of the QT interval | Q36896867 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 | ||
| Gene therapy to treat cardiovascular disease | Q37310450 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| Management of hypertension in angiogenesis inhibitor-treated patients | Q37371312 | ||
| Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature | Q37424209 | ||
| Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 | ||
| Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 | ||
| Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists | Q37844293 | ||
| Targeted therapies for renal cell carcinoma: review of adverse event management strategies | Q37974894 | ||
| Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials | Q38073936 | ||
| Vascular endothelial growth factor in heart failure | Q38121727 | ||
| Hypertension as a risk factor for heart failure | Q38208967 | ||
| Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups | Q38237318 | ||
| Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway | Q38237495 | ||
| Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors | Q38313896 | ||
| Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit | Q38501976 | ||
| Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models | Q39413387 | ||
| Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. | Q39514813 | ||
| Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. | Q40551173 | ||
| Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase | Q42450205 | ||
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. | Q42669075 | ||
| Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study | Q43281857 | ||
| Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies | Q43559046 | ||
| Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. | Q44454368 | ||
| Bevacizumab, bleeding, thrombosis, and warfarin | Q44583981 | ||
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 | ||
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 | ||
| Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial | Q47255118 | ||
| Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. | Q52524245 | ||
| Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. | Q52884682 | ||
| The Accelerated Approval of Oncologic Drugs | Q57765802 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 1067-1080 | |
| P577 | publication date | 2016-02-22 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management | |
| P478 | volume | 12 |
Search more.